Year-End Report April 2024 - March 2025
Regulatory
Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
Welcome to EQL Pharma's Investor Pages!
We strive to have an open and proactive dialogue with our shareholders.
Read MoreInterim Report Q3 2024/2025
Listen to CEO Axel Schörling present EQL Pharma's latest report.
Interim Report Q3 2024/2025Press Releases
Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2024/25, on Thursday, May 8[th], before stock markets open.
EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin)
EQL has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan (melatonin) for the GCC (Gulf Cooperation Council) region comprising of United Arab Emirates, Saud...
EQL Pharma in Short
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about us